Abstract


Bookmark and Share

Comparison of usefulness of simvastatin 20 mg versus 80 mg in preventing contrast-induced nephropathy in patients with acute coronary syndrome undergoing percutaneous coronary intervention

Xinwei J, Xianghua F, Jing Z, Xinshun G, Ling X, Weize F, Guozhen H, Yunfa J, Weili W, Shiqiang L.
Am J Cardiol 2009;104:519-524


Contrast-induced nephropathy limits the outcomes of percutaneous coronary intervention (PCI). The present study compared the protective effects of different statin doses on renal function. A total of 228 patients with acute coronary syndrome undergoing selective PCI were randomly divided into simvastatin 20-mg group (S20, n = 115) and simvastatin 80-mg group (S80, n = 113). Serum creatinine was measured at admission, the day of PCI, and 24 and 48 hours after PCI. The creatinine clearance was calculated using the Cochcroft-Gault formula. High-sensitive C-reactive protein, P-selectin, and intercellular adhesion molecule-1 were also measured before and after the procedure. Contrast-induced nephropathy was defined as a postprocedure increase in serum creatinine of > or =0.5 mg/dl or >25% from baseline. The serum creatinine significantly increased after PCI, with the peak value occurring at 24 hours, and then began to decrease. At 48 hours, the serum creatinine had decreased to the baseline level in the S80 group, but it had failed to do so in the S20 group. At 24 and 48 hours after PCI, the serum creatinine was lower in the S80 group than in the S20 group (p <0.05 and p <0.001, respectively). The creatinine clearance significantly decreased after PCI, with the lowest value occurring at 24 hours, and then it began to increase. In the S80 group, the creatinine clearance recovered to baseline level at 48 hours, but it failed to do so in the S20 group. The creatinine clearance was greater at 24 and 48 hours in the S80 group than that in the S20 group. Although the procedure caused a significant increase in high-sensitive C-reactive protein, P-selectin, and intercellular adhesion molecule-1 levels, the value was lower in the S80 group than in the S20 group (p <0.001). In conclusion, pretreatment with simvastatin 80 mg before PCI could further decrease the occurrence of contrast-induced nephropathy compared with simvastatin 20 mg. This benefit was associated with the lowering of high-sensitive C-reactive protein, P-selectin, and intercellular adhesion molecule-1 levels.

 

Am J Cardiol 2009;104:519 -524

 


Area Soci

Eventi

38° Congresso Nazionale


38° Congresso Nazionale

Bologna, 1-3 dicembre 2024

[continua a leggere]

Congresso Regionale SISA Sezione Campania

Napoli, 13 Dicembre 2023

[continua a leggere]

Congresso Regionale SISA Sezione Siculo-Calabra

Catania, 3-4 Dicembre 2023

[continua a leggere]

SISA LIPID ACADEMY - Corso avanzato di lipidologia clinica

Modena, 22-23 Giugno 2023

[continua a leggere]

Giornale Italiano Arteriosclerosi

Rivista in lingua italiana
riservata ai Soci SISA
Ultimo numero:
Anno 14 • N.4/2023

[continua a leggere]

HoFH today

Rivista Italiana della
Ipercolesterolemia
Familiare Omozigote
Anno 5 • N.1/2023

[continua a leggere]

Rivista NMCD

Nutrition, Metabolism and Cardiovascular Diseases

Istruzioni per l'accesso online

IF 2018: 3.340


Diateca

EAS Lipid Clinic Webinar - Le linee guida per le dislipidemie: presente e futuro
[continua a leggere]
EAS Advanced Course in Rare Lipid Disease
[continua a leggere]

Newsletter

Per essere informati sulle novità di S.I.S.A. iscrivetevi alla nostra newsletter inserendo
il vostro indirizzo di posta elettronica

Progetto LIPIGEN

LIPIGEN
Nuovo sito dedicato al Progetto LIPIGEN

 

Progetto LIPIGEN - Vecchio portale
E' necessario essere loggati come utente
Lipigen per poter accedere alla pagina

PROject Statin Intolerance SISA

 

PROSISA – PROject Statin Intolerance SISA
E' necessario essere loggati come utente
PROSISA per poter accedere alla pagina

GILA - Lipoprotein Aferesi

 

Gruppo Interdisciplinare Lipoprotein Aferesi
(Accesso Gruppo GILA-Lipoprotein Aferesi)

E' necessario essere loggati come utente del Gruppo GILA per poter accedere

 

Gruppo Interdisciplinare Lipoprotein Aferesi
(Documentazione ad accesso libero)

Pagina informativa per medici e pazienti